Jacqueline Boultwood

List of Publications by Year
in descending order

148 papers	10,783 citations	47006 47 h-index	33894 99 g-index
151 all docs	151 docs citations	151 times ranked	11193 citing authors

#	Article	IF	Citations
1	Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood, 2013, 122, 3616-3627.	1.4	1,562
2	Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature Genetics, 2010, 42, 722-726.	21.4	1,034
3	Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood, 2011, 118, 6239-6246.	1.4	457
4	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	30.7	372
5	Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nature Genetics, 2013, 45, 18-24.	21.4	359
6	A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5qâ€“ syndrome. Nature Medicine, 2010, 16, 59-66.	30.7	312
7	Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells InÂVivo. Cancer Cell, 2014, 25, 794-808.	16.8	272
8	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
9	Narrowing and genomic annotation of the commonly deleted region of the 5qâ˜ syndrome. Blood, 2002, 99, 4638-4641.	1.4	247
10	Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 11406-11411.	7.1	230
11	Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood, 2006, 108, 337-345.	1.4	198
12	Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nature Communications, 2015, 6, 5901.	12.8	196
13	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia, 2019, 33, 1747-1758.	7.2	195
14	SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood, 2020, 136, 157-170.	1.4	195
15	Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood, 2012, 120, 2076-2086.	1.4	181
16	Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. Blood, 2018, 132, 1225-1240.	1.4	168
17	Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood, 2012, 120, 1290-1298.	1.4	165
18	U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nature Cell Biology, 2019, 21, 640-650.	10.3	165

#	Article	IF	Citations
19	Inhibition of the TGF-Î² receptor I kinase promotes hematopoiesis in MDS. Blood, 2008, 112, 3434-3443.	1.4	157
20	IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood, 2015, 125, 3144-3152.	1.4	149
21	Gene expression profiling of CD34⁺ cells in patients with the 5qâ^' syndrome. British Journal of Haematology, 2007, 139, 578-589.	2.5	146
22	Identification of a BRCA1-mRNA Splicing Complex Required for Efficient DNA Repair and Maintenance of Genomic Stability. Molecular Cell, 2014, 54, 445-459.	9.7	146
23	Gene silencing by DNA methylation in haematological malignancies. British Journal of Haematology, 2007, 138, 3-11.	2.5	135
24	Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood, 2009, 114, 3538-3545.	1.4	135
25	Identification of acquired somatic mutations in the gene encoding chromatin-remodeling factor ATRX in the Î±-thalassemia myelodysplasia syndrome (ATMDS). Nature Genetics, 2003, 34, 446-449.	21.4	132
26	Advances in the 5qâ^' syndrome. Blood, 2010, 116, 5803-5811.	1.4	115
27	Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood, 2015, 125, 499-503.	1.4	115
28	Reduced SMAD7 Leads to Overactivation of TGF-Î² Signaling in MDS that Can Be Reversed by a Specific Inhibitor of TGF-Î² Receptor I Kinase. Cancer Research, 2011, 71, 955-963.	0.9	114
29	The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring Sideroblasts. PLoS ONE, 2008, 3, e1970.	2.5	113
30	Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood, 2012, 119, 6109-6117.	1.4	105
31	Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica, 2009, 94, 1762-1766.	3.5	99
32	Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes. Cell Reports, 2017, 20, 572-585.	6.4	99
33	The molecular pathogenesis of the myelodysplastic syndromes. European Journal of Haematology, 2015, 95, 3-15.	2.2	92
34	Haploinsufficiency of RPS14 in 5qâ^' syndrome is associated with deregulation of ribosomalâ€•and translationâ€•related genes. British Journal of Haematology, 2008, 142, 57-64.	2.5	91
35	The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts. Leukemia, 2013, 27, 889-896.	7.2	89
36	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. Blood, 2015, 126, 907-907.	1.4	85

#	Article	IF	Citations
37	Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology. British Journal of Haematology, 2004, 125, 576-583.	2.5	75
38	Cell-specific proteome analyses of human bone marrow reveal molecular features of age-dependent functional decline. Nature Communications, 2018, 9, 4004.	12.8	71
39	Molecular cytogenetic delineation of the critical deleted region in the 5qâ˜ syndrome. , 1998, 22, 251-256.		70
40	The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes. Journal of Clinical Investigation, 2017, 127, 2206-2221.	8.2	69
41	Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. Journal of Clinical Investigation, 2018, 128, 5479-5488.	8.2	68
42	SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function. Cell Stem Cell, 2018, 23, 355-369.e9.	11.1	68
43	Induction of p53 and up-regulation of the p53 pathway in the human 5qâ˜ syndrome. Blood, 2010, 115, 2721-2723.	1.4	65
44	Gene expression and risk of leukemic transformation in myelodysplasia. Blood, 2017, 130, 2642-2653.	1.4	64
45	Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/Î²-Catenin Activation. Cancer Research, 2017, 77, 4846-4857.	0.9	61
46	SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications. Leukemia, 2020, 34, 2525-2530.	7.2	61
47	Mutation Patterns of 16 Genes in Primary and Secondary Acute Myeloid Leukemia (AML) with Normal Cytogenetics. PLoS ONE, 2012, 7, e42334.	2.5	60
48	ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts. Oncotarget, 2015, 6, 44061-44071.	1.8	52
49	TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16127-16132.	7.1	51
50	PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome. Blood, 2015, 126, 1118-1127.	1.4	49
51	Application of CRISPR/Cas9 genome editing to the study and treatment of disease. Archives of Toxicology, 2015, 89, 1023-1034.	4.2	47
52	Identification of Gene Expressionâ€“Based Prognostic Markers in the Hematopoietic Stem Cells of Patients With Myelodysplastic Syndromes. Journal of Clinical Oncology, 2013, 31, 3557-3564.	1.6	45
53	Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6359-68.	7.1	45
54	Clonality in the Myelodysplastic Syndromes. International Journal of Hematology, 2001, 73, 411-415.	1.6	42

#	Article	IF	Citations
55	Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays. Haematologica, 2008, 93, 994-1000.	3.5	42
56	Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS. Blood, 2014, 124, 780-790.	1.4	42
57	Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q- syndrome. Genes Chromosomes and Cancer, 2000, 29, 276-280.	2.8	41
58	Mutations in <scp>SETBP</scp>1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression. British Journal of Haematology, 2013, 163, 235-239.	2.5	37
59	Chromosomal Deletions in Myelodysplasia. Leukemia and Lymphoma, 1995, 17, 71-78.	1.3	36
60	Transcription Mapping of the 5qâ^' Syndrome Critical Region: Cloning of Two Novel Genes and Sequencing, Expression, and Mapping of a Further Six Novel cDNAs. Genomics, 2000, 66, 26-34.	2.9	34
61	Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations. Haematologica, 2017, 102, 498-508.	3.5	34
62	Recurrent genetic defects on chromosome 5q in myeloid neoplasms. Oncotarget, 2017, 8, 6483-6495.	1.8	34
63	Activation of the mTOR pathway by the amino acid l-leucine in the 5q- syndrome and other ribosomopathies. Advances in Biological Regulation, 2013, 53, 8-17.	2.3	33
64	RECENT ADVANCES IN THE 5Q- SYNDROME. Mediterranean Journal of Hematology and Infectious Diseases, 2015, 7, e2015037.	1.3	32
65	Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Cancer Research, 2016, 76, 4841-4849.	0.9	32
66	Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of Gâ€CSF. British Journal of Haematology, 2010, 149, 844-854.	2.5	31
67	The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes. Advances in Biological Regulation, 2014, 54, 153-161.	2.3	31
68	Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome. Advances in Biological Regulation, 2012, 52, 196-203.	2.3	29
69	Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes. Haematologica, 2013, 98, 1856-1864.	3.5	29
70	Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications. Advances in Biological Regulation, 2017, 63, 59-70.	2.3	29
71	ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine. Blood Cancer Journal, 2021, 11, 157.	6.2	27
72	NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q). Haematologica, 2004, 89, 865-6.	3.5	27

#	Article	IF	Citations
73	Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes. Leukemia, 2019, 33, 2276-2290.	7.2	25
74	The Effects of Severe Hypoxia on Glycolytic Flux and Enzyme Activity in a Model of Solid Tumors. Journal of Cellular Biochemistry, 2016, 117, 1890-1901.	2.6	23
75	Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches. Advances in Biological Regulation, 2018, 67, 13-29.	2.3	21
76	De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways. Haematologica, 2019, 104, 1789-1797.	3.5	21
77	Novel Genes Mapping to the Critical Region of the 5qâ^' Syndrome. Genomics, 1997, 45, 88-96.	2.9	20
78	Silencing of <scp>ASXL</scp>1 impairs the granulomonocytic lineage potential of human <scp>CD</scp>34⁺ progenitor cells. British Journal of Haematology, 2013, 160, 842-850.	2.5	19
79	CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q). British Journal of Haematology, 2015, 171, 210-214.	2.5	19
80	Splicing factor mutant myelodysplastic syndromes: Recent advances. Advances in Biological Regulation, 2020, 75, 100655.	2.3	18
81	Gene expression profiling in the myelodysplastic syndromes. Hematology, 2005, 10, 281-287.	1.5	17
82	MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. Cancer Cell, 2021, 39, 529-547.e7.	16.8	17
83	Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes. Current Pharmaceutical Design, 2016, 22, 2333-2344.	1.9	17
84	The Role of Haploinsufficiency of rps14 and p53 Activation in the Molecular Pathogenesis of the 5q- Syndrome. Mental Illness, 2011, 3, e10.	0.8	14
85	Application of genome editing technologies to the study and treatment of hematological disease. Advances in Biological Regulation, 2016, 60, 122-134.	2.3	14
86	Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia. British Journal of Haematology, 2004, 126, 508-511.	2.5	12
87	SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML. Blood, 2019, 134, 4224-4224.	1.4	12
88	GFI136N as a therapeutic and prognostic marker for myelodysplastic syndrome. Experimental Hematology, 2016, 44, 590-595.e1.	0.4	11
89	PRR14L mutations are associated with chromosome 22 acquired uniparental disomy, age-related clonal hematopoiesis and myeloid neoplasia. Leukemia, 2019, 33, 1184-1194.	7.2	11
90	CUX1 in leukemia: dosage matters. Blood, 2013, 121, 869-871.	1.4	10

#	Article	IF	Citations
91	Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy. International Journal of Cancer, 2016, 139, 1402-1413.	5.1	10
92	HOMOZYGOUS DELETION OF FMS IN A PATIENT WITH THE 5qâ€" SYNDROME. British Journal of Haematology, 1990, 76, 310-311.	2.5	9
93	SF3B1 mutant myelodysplastic syndrome: Recent advances. Advances in Biological Regulation, 2021, 79, 100776.	2.3	8
94	Reduced translation of GATA1 in Diamond-Blackfan anemia. Nature Medicine, 2014, 20, 703-704.	30.7	7
95	Non-del(5q) myelodysplastic syndromesâ€"associated loci detected by SNP-array genome-wide association meta-analysis. Blood Advances, 2019, 3, 3579-3589.	5.2	7
96	Recent advances in MDS mutation landscape: Splicing and signalling. Advances in Biological Regulation, 2020, 75, 100673.	2.3	7
97	Marked downâ€regulation of nucleophosminâ€1 is associated with advanced del(5q) myelodysplastic syndrome. British Journal of Haematology, 2011, 155, 272-274.	2.5	6
98	Application of induced pluripotent stem cell technology for the investigation of hematological disorders. Advances in Biological Regulation, 2019, 71, 19-33.	2.3	6
99	Downregulation of Ribosomal Proteins Is Seen in Non 5q- MDS. Blood, 2008, 112, 854-854.	1.4	6
100	TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee. Blood, 2014, 124, 532-532.	1.4	6
101	Phospholipase C beta1 (Plâ€PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during ironâ€induced oxidative stress in myelodysplastic syndromes (MDS). FASEB Journal, 2020, 34, 15400-15416.	0.5	5
102	Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion. British Journal of Haematology, 2016, 173, 161-165.	2.5	4
103	L-leucine increases translation of RPS14 and LARP1 in erythroblasts from del(5q) myelodysplastic syndrome patients. Haematologica, 2018, 103, e496-e500.	3.5	4
104	BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome. International Journal of Molecular Sciences, 2021, 22, 10658.	4.1	4
105	5q- syndrome. Current Pharmaceutical Design, 2012, 18, 3180-3183.	1.9	4
106	Clinical and Genomic Characterization of Chromosome 7 Lesions in Myeloid Malignancies,. Blood, 2011, 118, 3549-3549.	1.4	4
107	Structure of the granulocyte macrophage colony-stimulating factor gene in patients with the myelodysplastic syndromes. American Journal of Hematology, 1990, 34, 157-158.	4.1	3
108	Somatic Mutation of SF3B1, a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts. Blood, 2011, 118, 3-3.	1.4	3

#	Article	IF	Citations
109	PRACTICAL CONSIDERATIONS IN THE ANALYSIS OF CHROMOSOMAL DELETION BREAKPOINTS BY PULSED FIELD GEL ELECTROPHORESIS. British Journal of Haematology, 1991, 77, 129-130.	2.5	2
110	Physical mapping of the MEGF1 gene, human homologue of the Drosophila tumour suppressor gene fat, to the critical region of the 5q-syndrome. GeneScreen, 2001, 1, 165-167.	0.6	2
111	The impact of spliceosome mutations in MDS. HemaSphere, 2019, 3, 132-134.	2.7	2
112	The utilisation of glutamine and glucose by a 3-D tumour model trapped in quiescence. International Journal of Biochemistry and Cell Biology, 2021, 133, 105935.	2.8	2
113	Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells.. Blood, 2009, 114, 735-735.	1.4	2
114	Mutation Analysis of TET2 Reveals the Clonal Nature of Refractory Anemia with Ring Sideroblasts. Blood, 2010, 116, 1862-1862.	1.4	2
115	Aberrant Expression of DOCK4 Leads to Disruption of the F-Actin Skeleton and Altered Membrane Stability in MDS Erythroblasts and Mature Erythrocytes. Blood, 2012, 120, 924-924.	1.4	2
116	Targeting MDS and AML Stem Cells with AZD-9150 Mediated Inhibition of STAT3. Blood, 2016, 128, 4314-4314.	1.4	2
117	Spliceosome mutations: 1 plus 1 does not always equal 2. Blood, 2020, 136, 1471-1472.	1.4	1
118	Lenalidomide Up-Regulates SPARC and Inhibits In Vitro Growth of the Malignant Clone in Myelodysplastic Syndrome Patients with 5q Deletion.. Blood, 2006, 108, 855-855.	1.4	1
119	Gene Expression Profiling of Day 7 Erythroblasts from RARS Before and after Treatment with G-CSF.. Blood, 2007, 110, 2427-2427.	1.4	1
120	Frequent Mutation of the Polycomb-Associated Gene ASXL1 In Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia. Blood, 2010, 116, 2940-2940.	1.4	1
121	Association Between Gene Expression Profiles and Commonly Mutated Genes In The Hematopoietic Stem Cells Of Patients With Myelodysplastic Syndromes. Blood, 2013, 122, 2779-2779.	1.4	1
122	Inhibition Of CXCR2 As a Therapeutic Strategy In AML and MDS. Blood, 2013, 122, 484-484.	1.4	1
123	Clonal Heterogeneity in the 5q- Syndrome: NPMc+ and p53 Expressing Progenitors Are Insensitive to Lenalidomide Treatment and Expand at Disease Progression. Blood, 2008, 112, 5104-5104.	1.4	1
124	Frequent Mutation of the Polycomb-Associated Gene ASXL1 in the Myelodysplastic Syndromes and in Acute Myeloid Leukaemia.. Blood, 2009, 114, 419-419.	1.4	1
125	Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells. Blood, 2010, 116, 298-298.	1.4	1
126	Activation of the mTOR Signaling Pathway by L-Leucine in RPS14-Deficient Erythroid Cells. Blood, 2012, 120, 171-171.	1.4	1

#	Article	IF	Citations
127	Analysis of Clonal Hierarchy Shows That Other Ancestral Events May Precede Evolution of Del(5q) in Myeloid Neoplasms. Blood, 2014, 124, 4605-4605.	1.4	1
128	BRAC2 gene deletion is rare in chronic lymphocytic leukemia. , 1998, 59, 318-318.		0
129	Molecular Pathogenesis of the 5qâ€“ Syndrome: The Role of RPS14 in Pathogenesis and SPARC in the Hematologic Response to Lenalidomide. Clinical Leukemia, 2008, 2, 182-186.	0.2	0
130	Clinical associations of CSNK1A1 mutation in myelodysplastic syndrome. Lancet Haematology,the, 2015, 2, e182-e183.	4.6	0
131	Expression Profiling of CD34+ Cells in Patients with Myelodysplastic Syndromes with and without a del(5q).. Blood, 2004, 104, 2363-2363.	1.4	0
132	High-Resolution Genomic Profiling of Myelodysplasia (MDS) by Microarray Comparative Genomic Hybridization (CGH).. Blood, 2006, 108, 2645-2645.	1.4	0
133	Expression Profiling of CD34+ Cells in Patients with Myelodysplastic Syndromes: Involvement of Interferon-Stimulated Genes and Correlation to FAB Subtype and Karyotype.. Blood, 2006, 108, 2626-2626.	1.4	0
134	Gene Expression Profiling of CD34+ Cells in Patients with Myelodysplastic Syndromes. Blood, 2008, 112, 3642-3642.	1.4	0
135	Haploinsufficiency of RPS14 and Deregulation of Ribosomal- and Translation-Related Genes in MDS Patients with Del(5q). Blood, 2008, 112, 3641-3641.	1.4	0
136	Investigation of the Molecular Action of Bortezomib Treatment In Multiple Myeloma. Blood, 2010, 116, 5038-5038.	1.4	0
137	The Proliferation Inhibitor CDKN1C (P57KIP2) Is Over Expressed in CD34+ Cells of Patients with MDS and Determines a Worse Prognosis Independently of IPSS Score Factors. Blood, 2012, 120, 3820-3820.	1.4	0
138	Identification of Gene Expression Based Prognostic Markers in the Hematopoietic Stem Cells of Patients with Myelodysplastic Syndromes. Blood, 2012, 120, 3857-3857.	1.4	0
139	Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia Abrogate an Ubiquitination Site and Dysregulate SETBP1 Protein Levels. Blood, 2012, 120, LBA-2-LBA-2.	1.4	0
140	Aberrant Overexpression Of CD14 In Granulocytes Sensitizes Innate Immune Response In mDia1 Heterozygous Myelodysplastic Syndromes. Blood, 2013, 122, 1557-1557.	1.4	0
141	Whole Exome Sequencing (â€œmutatomeâ€) Of Deletion 5q. Blood, 2013, 122, 656-656.	1.4	0
142	Aberration Of SF3B1 Results In Deregulated Splicing Of Key Genes and Pathways In Myelodysplastic Syndromes. Blood, 2013, 122, 2747-2747.	1.4	0
143	Efficacy of Dual Inhibition of p38 Mitogen Activated Protein Kinase (MAPK) and Tie-2 Kinase in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood, 2014, 124, 4628-4628.	1.4	0
144	PAK1 Is a Therapeutic Target in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2014, 124, 4614-4614.	1.4	0

#	Article	IF	Citations
145	An Integrative Genomics Approach Uncovers the Basis of Resistance to AZA Therapy in MDS and CMML. Blood, 2015, 126, 710-710.	1.4	0
146	Progression in Patients with with Low- and Intermediate-1 Risk Del(5q) MDS Is Predicted By a Limited Subset of Mutations. Blood, 2016, 128, 4329-4329.	1.4	0
147	Sequential Analysis of miRNA Profiling during Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes. Blood, 2020, 136, 6-7.	1.4	0
148	Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses. Blood, 2020, 136, 45-45.	1.4	0